ZA9425B - Compositions containing esters of unsaturated fatty acids - Google Patents
Compositions containing esters of unsaturated fatty acidsInfo
- Publication number
- ZA9425B ZA9425B ZA9425A ZA9425A ZA9425B ZA 9425 B ZA9425 B ZA 9425B ZA 9425 A ZA9425 A ZA 9425A ZA 9425 A ZA9425 A ZA 9425A ZA 9425 B ZA9425 B ZA 9425B
- Authority
- ZA
- South Africa
- Prior art keywords
- fatty acids
- compositions containing
- unsaturated fatty
- containing esters
- fatty acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Optical Recording Or Reproduction (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939300125A GB9300125D0 (en) | 1993-01-06 | 1993-01-06 | Compositions containing esters of unsaturated fatty acids |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA9425B true ZA9425B (en) | 1994-08-19 |
Family
ID=10728334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9425A ZA9425B (en) | 1993-01-06 | 1994-01-04 | Compositions containing esters of unsaturated fatty acids |
Country Status (17)
Country | Link |
---|---|
US (1) | US5604216A (fr) |
EP (1) | EP0606012B1 (fr) |
JP (1) | JPH06234644A (fr) |
KR (1) | KR940018088A (fr) |
CN (1) | CN1096197A (fr) |
AT (1) | ATE168267T1 (fr) |
AU (1) | AU673555B2 (fr) |
CA (1) | CA2112824A1 (fr) |
DE (1) | DE69319710T2 (fr) |
DK (1) | DK0606012T3 (fr) |
ES (1) | ES2119871T3 (fr) |
GB (1) | GB9300125D0 (fr) |
MY (1) | MY110765A (fr) |
NO (1) | NO940035D0 (fr) |
NZ (1) | NZ250583A (fr) |
RU (1) | RU2142468C1 (fr) |
ZA (1) | ZA9425B (fr) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6107499A (en) * | 1988-02-26 | 2000-08-22 | Neuromedica, Inc. | Dopamine analog amide |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US5955459A (en) * | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
US6197764B1 (en) | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
US6153653A (en) * | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
US6149964A (en) * | 1998-05-21 | 2000-11-21 | Beech-Nut Nutrition Corporation | Egg yolk-containing baby food compositions and methods therefor |
US6579551B1 (en) | 1998-05-21 | 2003-06-17 | Beech-Nut Nutrition Corporation | Baby-food compositions containing egg yolk and methods therefor |
US7141266B2 (en) * | 1998-05-21 | 2006-11-28 | Beech-Nut Nutrition Corporation | Baby-food compositions enhancing visual acuity and methods therefor |
US7413759B2 (en) * | 1998-05-21 | 2008-08-19 | Beech-Nut Nutrition Corporation | Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions |
NZ333817A (en) * | 1998-08-25 | 2000-09-29 | Mcneil Ppc Inc | Process for preparing stanol/sterol fatty acid esters such as beta sitosterol fatty acid esters, useful in reducing cholesterol levels |
US5892068A (en) * | 1998-08-25 | 1999-04-06 | Mcneil-Ppc, Inc. | Preparation of sterol and stanol-esters |
AU2006201772B2 (en) * | 1999-01-27 | 2010-02-04 | Amarin Neuroscience Limited | Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
US7235583B1 (en) * | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
AU775774C (en) * | 1999-04-15 | 2005-05-19 | Kaneka Corporation | Peroxisome proliferator-activated receptor agonist |
US6998501B1 (en) * | 1999-08-30 | 2006-02-14 | Ocean Nutrition Canada Limited | Nutritional supplement for lowering serum triglyceride and cholesterol levels |
WO2001015552A1 (fr) * | 1999-08-30 | 2001-03-08 | Ocean Nutrition Canada Ltd. | Supplement nutritionnel destine a abaisser le taux de cholesterol et de triglycerides seriques |
US20030206958A1 (en) * | 2000-12-22 | 2003-11-06 | Cattaneo Maurizio V. | Chitosan biopolymer for the topical delivery of active agents |
EP1121928B1 (fr) * | 2000-01-31 | 2008-01-23 | Härting S.A. | Compositions contenant des ester d'acides gras de phytostérol et policosanol pour réduire le niveau de cholésterol et des triglycérides |
KR20010091499A (ko) * | 2000-03-16 | 2001-10-23 | 김용범 | 레이저 그래픽 디스플레이 장치 |
JP2005500988A (ja) | 2001-03-23 | 2005-01-13 | ルイトポルド・ファーマシューティカルズ・インコーポレーテッド | 脂肪族アミン薬物複合体 |
ATE556706T1 (de) * | 2001-03-23 | 2012-05-15 | Luitpold Pharm Inc | Fettalkohol-arzneimittel-konjugate |
JP2003048831A (ja) * | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
DE10154221A1 (de) * | 2001-11-07 | 2003-05-15 | Max Delbrueck Centrum | Mittel zur Behandlung von Läsionen des Nervensystems |
US20050123500A1 (en) * | 2003-01-31 | 2005-06-09 | The Procter & Gamble Company | Means for improving the appearance of mammalian hair and nails |
EP1587377A2 (fr) * | 2003-01-31 | 2005-10-26 | The Procter & Gamble Company | Moyen pour ameliorer l'aspect de tissus keratiniques de mammiferes |
CA2529735C (fr) * | 2003-06-20 | 2012-07-10 | Mochida Pharmaceutical Co., Ltd. | Composition pour la prevention et le traitement des varices des membres inferieures |
CA2436650A1 (fr) * | 2003-08-06 | 2005-02-06 | Naturia Inc. | Compositions d'acides linoleniques conjugues : synthese, purification et utilisations |
US20060141046A1 (en) * | 2004-05-06 | 2006-06-29 | Ivrea Pharmaceuticals, Inc. | Particles for the delivery of active agents |
US20050281886A1 (en) * | 2004-05-06 | 2005-12-22 | Ivrea Pharmaceuticals, Inc. | Particles for the delivery of active agents |
RU2444356C2 (ru) * | 2005-07-08 | 2012-03-10 | Мартек Байосайенсиз Корпорейшн | Полиненасыщенные жирные кислоты для лечения деменции и состояний, связанных с преддеменцией |
US20080110624A1 (en) * | 2005-07-15 | 2008-05-15 | Halliburton Energy Services, Inc. | Methods for controlling water and particulate production in subterranean wells |
ITMI20052377A1 (it) * | 2005-12-13 | 2007-06-14 | Anna Petroni | Medicamento a base di monoestere di steroidi con acidi grassi a catena lunga |
FR2902659A1 (fr) * | 2006-06-23 | 2007-12-28 | Pierre Fabre Medicament Sa | Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires |
EP2334295B1 (fr) | 2008-09-02 | 2017-06-28 | Amarin Pharmaceuticals Ireland Limited | Composition pharmaceutique comprenant de l'acide eïcosapentaénoïque et de l'acide nicotinique et ses procédés d'utilisation |
AU2010213899B2 (en) | 2009-02-10 | 2014-02-06 | Amarin Pharmaceuticals Ireland Limited | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
EP3278665B1 (fr) | 2009-04-29 | 2020-09-09 | Amarin Pharmaceuticals Ireland Limited | Composition pharmaceutique stable et procédés d'utilisation associés |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
CN108096209A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
CN102656153B (zh) * | 2009-10-29 | 2015-02-18 | 延世大学校产学协力团 | 新型血管渗漏阻断剂 |
NZ611606A (en) | 2010-11-29 | 2015-10-30 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
EP2775837A4 (fr) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | Méthodes de traitement de l'hypertriglycéridémie |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
KR20150036252A (ko) | 2012-06-29 | 2015-04-07 | 애머린 파마슈티칼스 아일랜드 리미티드 | 스타틴 요법 중인 대상체에서 심혈관 사건의 위험을 감소시키는 방법 |
US9717741B2 (en) | 2012-10-11 | 2017-08-01 | Anaplasi Pharmaceuticals Llc | Method and compositions for treating psoriasis |
JP6059352B2 (ja) * | 2012-10-11 | 2017-01-11 | アナプラシ ファーマシューティカルズ エルエルシー | 乾癬を治療するための方法及び組成物 |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
JP6224203B2 (ja) * | 2016-12-08 | 2017-11-01 | アナプラシ ファーマシューティカルズ エルエルシー | 乾癬を治療するための組成物 |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
JP6491293B2 (ja) * | 2017-10-04 | 2019-03-27 | アナプラシ ファーマシューティカルズ エルエルシー | 乾癬を治療するためのエアロゾル、ムース、又はフォームの組成物 |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
EP3750536A1 (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ireland Limited | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
JP6728425B2 (ja) * | 2019-02-28 | 2020-07-22 | アナプラシ ファーマシューティカルズ エルエルシー | 乾癬を治療するためのクリーム、ローション、又はゲルの組成物 |
US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
-
1993
- 1993-01-06 GB GB939300125A patent/GB9300125D0/en active Pending
- 1993-12-23 NZ NZ250583A patent/NZ250583A/xx unknown
- 1993-12-29 EP EP93310599A patent/EP0606012B1/fr not_active Expired - Lifetime
- 1993-12-29 DK DK93310599T patent/DK0606012T3/da active
- 1993-12-29 DE DE69319710T patent/DE69319710T2/de not_active Expired - Fee Related
- 1993-12-29 AT AT93310599T patent/ATE168267T1/de not_active IP Right Cessation
- 1993-12-29 ES ES93310599T patent/ES2119871T3/es not_active Expired - Lifetime
- 1993-12-30 AU AU52763/93A patent/AU673555B2/en not_active Ceased
-
1994
- 1994-01-04 ZA ZA9425A patent/ZA9425B/xx unknown
- 1994-01-04 MY MYPI94000009A patent/MY110765A/en unknown
- 1994-01-05 CA CA002112824A patent/CA2112824A1/fr not_active Abandoned
- 1994-01-05 NO NO940035A patent/NO940035D0/no unknown
- 1994-01-05 RU RU94000061A patent/RU2142468C1/ru active
- 1994-01-06 KR KR1019940000159A patent/KR940018088A/ko not_active Application Discontinuation
- 1994-01-06 US US08/178,553 patent/US5604216A/en not_active Expired - Fee Related
- 1994-01-06 JP JP6000338A patent/JPH06234644A/ja active Pending
- 1994-01-06 CN CN94100242A patent/CN1096197A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69319710T2 (de) | 1999-03-11 |
AU673555B2 (en) | 1996-11-14 |
KR940018088A (ko) | 1994-08-16 |
GB9300125D0 (en) | 1993-03-03 |
CN1096197A (zh) | 1994-12-14 |
CA2112824A1 (fr) | 1994-07-07 |
NO940035L (fr) | 1994-07-07 |
DK0606012T3 (da) | 1999-04-19 |
ES2119871T3 (es) | 1998-10-16 |
RU2142468C1 (ru) | 1999-12-10 |
ATE168267T1 (de) | 1998-08-15 |
EP0606012B1 (fr) | 1998-07-15 |
US5604216A (en) | 1997-02-18 |
DE69319710D1 (de) | 1998-08-20 |
AU5276393A (en) | 1994-07-14 |
JPH06234644A (ja) | 1994-08-23 |
MY110765A (en) | 1999-03-31 |
NZ250583A (en) | 1997-08-22 |
EP0606012A1 (fr) | 1994-07-13 |
NO940035D0 (no) | 1994-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA9425B (en) | Compositions containing esters of unsaturated fatty acids | |
RU94000061A (ru) | Эфиры холестерина и ненасыщенных жирных кислот, способ лечения и фармацевтическая или косметическая композиция | |
AU2080988A (en) | Esters of 13-trans-retinoic acid | |
AU7053494A (en) | Method of treating coronary vascular disease using docosahexaenoic acid | |
CA2086429A1 (fr) | Composition pharmaceutique ou cosmetique contenant en association un retinoide et un sterol | |
CA2144312A1 (fr) | Acides aliphatiques dicarboxyliques non satures | |
AU7734391A (en) | Essential fatty acid treatment | |
TW429145B (en) | Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA | |
AU1821888A (en) | Treatment or prevention of memory loss using essential fatty acid compositions | |
GR3020393T3 (en) | Esters of l-carnitine and alkanoyl l-carnitines with glycolic acid or esters thereof and pharmaceutical compositions containing same for treating dermatoses. | |
AU660223B2 (en) | Fatty acid treatment | |
AU1340895A (en) | Fatty acid derivatives | |
AU1271592A (en) | Malic acid derivatives and compositions for the treatment of psoriasis | |
AU1145483A (en) | Linoleic acid and essential fatty acid compositions as | |
AU1438295A (en) | Method for treatment of papulo-pustules and comedones of the skin | |
TW223589B (fr) | ||
PL298321A1 (en) | Application of 7-oxo-7h-pyrido(1, 2, 3-de/1,4)benzoxazine-6-carboxylic acids and their esters as therapeutic agents and therapeutic agents containing them | |
ATE113291T1 (de) | Polyaromatische ester von makroliden antibiotika und linkosamiden antibiotika, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen und kosmetischen zusammensetzungen. | |
ATE113290T1 (de) | Nicht gesättigte cycloaliphatische ester von makroliden antibiotika und linkosamiden antibiotika, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen und kosmetischen zusammensetzungen. | |
SI0657431T1 (en) | 4-Phenyl-3-substituted 1,4-dihydropyridine esters with cerebral activity |